Rossari Biotech Limited has withdrawn its participation from the Nirmal Bang Semi-Annual Investor Conference scheduled for August 10, 2026, reversing a prior disclosure of its intent to attend. The company notified the stock exchanges of this change on August 06, 2026, citing an inability to participate in the planned one-on-one and group sessions in Mumbai. This development means investors will not have the opportunity to engage with management during the event as originally anticipated.

The intimation was submitted pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rossari Biotech referenced its earlier letter dated August 03, 2026, which had confirmed the company’s scheduled appearance at the conference. The updated disclosure explicitly states that the company "could not participate" in the event, superseding the previous announcement.

Withdrawal Details

Parul Gupta, Company Secretary & Head - Legal at Rossari Biotech, signed the non-participation notice on August 06, 2026. The communication was dispatched to both BSE Limited and the National Stock Exchange of India Limited for dissemination to stakeholders. No specific reason for the withdrawal, such as operational exigencies or management unavailability, was provided in the filing beyond the general statement of inability to participate.

Compliance Note

The company requested that the exchanges take the non-participation on record and disseminate the information to all concerned parties. This update ensures that market participants are aware that the previously announced interaction with Rossari Biotech management will not take place, allowing investors to adjust their schedules accordingly.

Rossari Biotech Limited reported its highest-ever quarterly revenue of ₹697.2 crore for Q1FY27, a 28% increase from ₹543.7 crore in the corresponding period of the previous year. The company's consolidated profit after tax (PAT) for the quarter stood at ₹35.1 crore, up 4% from ₹33.6 crore in Q1FY26. The Board of Directors approved the unaudited financial results for the quarter during a meeting held on July 18, 2026, with the statutory auditors subjecting the results to a limited review.

On the operational profitability front, EBITDA for the quarter came in at ₹80.6 crore, up from ₹67.9 crore in the year-ago period, reflecting an 18.7% year-on-year increase. However, the EBITDA margin contracted to 11.6% from 12.5% in the corresponding quarter of the previous year, indicating that while absolute operating profits grew alongside the strong revenue expansion, cost pressures moderated the margin performance.

Financial Results Summary

The table below presents a comparison of key financial metrics for the quarter:

Segment Performance

The company's core segments delivered strong growth, supported by a diversified portfolio and strong customer engagement across markets. Performance across Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC) and Animal Health and Nutrition (AHN) remained broad-based. HPPC contributed 79% to the business sector contribution in Q1FY27, while TSC and AHN contributed 15% and 6% respectively.

Excluding Institutional and B2C businesses, EBITDA margin in Q1FY27 stood at 14%, reflecting the underlying strength and stability of the core B2B business. Performance in the Institutional and B2C segments remained flat in Q1FY27, as the company continued its focus on portfolio rationalisation and improving the quality of revenues across these segments.

Management Guidance

During the earnings conference call held on July 20, 2026, management shared key guidance across growth, margins, capital expenditure, and emerging business segments. The Q1FY27 consolidated EBITDA margin of 11.6% is expected to serve as the baseline, with a target to reach 15%+ consolidated EBITDA margins in approximately two years. This margin improvement is expected to be driven by optimizing the product portfolio, exiting low-margin businesses, and achieving optimal utilization of expanded capacities.

Despite Q1FY27 revenue growing 28% year-on-year, management maintained its FY27 top-line growth guidance at 15%, citing global uncertainties. FY28 growth is anticipated to be better, assuming increased Ethylene Oxide (EO) availability by the end of the current calendar year. The table below summarizes the key guidance parameters shared during the concall:

Corporate Actions

The Board approved the grant of 4,000 stock options under the Rossari Employee Stock Option Plan - 2019 (ESOP 2019), with the exercise price determined at ₹531 per option. Additionally, the company allotted 2,500 equity shares of ₹2 each fully paid-up to grantees upon the exercise of options. Consequently, the issued and paid-up equity share capital increased to ₹11,07,88,232, consisting of 55,394,116 equity shares of ₹2 each.

Restructuring Approval

The Board approved the transfer of the company's 100% shareholding in Rossari International Limited Company (RILC), a wholly owned subsidiary, to Rossari (Singapore) Pte. Ltd., another wholly owned subsidiary. The proposed transfer is part of an internal group restructuring exercise aimed at establishing a common holding platform for overseas subsidiaries to simplify regulatory reporting. The transaction is subject to the execution of a Share Purchase Agreement and receipt of requisite approvals from the relevant authorities in the Kingdom of Saudi Arabia. The consideration for the sale of 9,000 shares is approximately ₹24 crore. The transaction is not expected to have any material impact on the company's consolidated financial position or operations.

Earnings Call Recording

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has informed that the audio recording of the earnings conference call held on July 20, 2026, is available on its website. The recording can be accessed under the 'Investor Call' section at www.rossari.com/announcement-2/ .